The purposes of this study were to determine the frequency of the yeast species obtained from patients with clinical features of onychomycosis and the in vitro antifungal susceptibility of the yeast species to propolis.
Methods:
A prospective study was carried out at the Mycology Research Center in Iran from 2010 to 2011. Clinical diagnosis was performed by direct microscopic examination and culture. Different yeast species were identified by morphological and biochemical tests. An antifungal susceptibility test to fluconazole (FLU) and propolis by the broth microdilution method was performed on each isolate.
Results:
One hundred and twenty-eight fungal isolates were obtained. The most prevalent fungi were yeasts (81, 63.2%), dermatophytes (36, 28.1%), and nondermatophyte fungi (11, 8.6%). Fingernails were more affected than toenails (65.4% vs. 19.8%, respectively). The most frequently found species was Candida albicans (38.5%), followed by Candida spp. (23.1%), C. tropicalis (10.8%), C. kefyr (6.2%), C. krusei (3.1%), Malassezia globosa (4.6%), M. slooffiae (4.6%), and M. pachydermatis (1.5%). Of all yeast isolates (65), seven showed resistance to FLU. The average MIC of propolis for FLU-susceptible isolates was 5.8 μg/mL, whereas this value was 12.25 μg/mL for FLU-resistant isolates.
Conclusion:
Our results proved that the propolis inhibits the growth of pathogenic yeasts and confirmed the efficiency of propolis as an anti-Candida and anti-Malassezia agent.
Get full access to this article
View all access options for this article.
References
1.
YenisehirliG, BulutY, SezerE, GundayE. Onychomycosis infections in the middle Black Sea region, Turkey. Int J Dermatol, 2009; 48:956–959.
2.
MurraySC, DawberRP. Onychomycosis of toenails: orthopaedic and podiatric considerations. Australas J Dermatol, 2002; 43:105–112.
3.
MigdleyG, MooreMK, CookkJC, PhanQG. Mycology of nail disorders. J Am Acad Derm, 1994; 31:68–74.
4.
GhannoumMA, HajjehRA, ScherR, KonnikovN, GuptaAK, SummerbellR, SullivanS, DanielR, KrusinskiP, FleckmanP, RichP, OdomR, AlyR, PariserD, ZaiacM, RebellG, LesherJ, GerlachB, Ponce-De-LeonGF, GhannoumA, WarnerJ, IshamN, ElewskiB. A large-scale North American study of fungal isolates from nails: the frequency of onychomycosis, fungal distribution, and antifungal susceptibility pattern. J Am Acad Dermato, 2002; 43:641–648.
5.
AraújoAJG, BastosOMP, SouzaMAJ, OliveiraJC. Onychomycosis caused by emergent fungi: clinical analysis, diagnosis and revision. An Bras Dermatol, 2003; 78:445–455.
RobertsDT, TaylorWD, BoyleJ. Guidelines for treatment of onychomycosis. Br J Dermatol, 2003; 148:402–410.
8.
DorkoE, JautovaJ, TkacikovaL, WantrubovaA. The frequency of Candida species in onychomycosis. Folia Microbiol, 2002; 47:727–731.
9.
MujicaMT, FinquelievichJL, JewtuchowiczV, IovannittiCA. Prevalence of Candida albicans and Candida non-albicans in clinical samples during 1999–2001. Rev Argent Microbiol, 2004; 36:107–112.
10.
ChiCC, WangSH, ChouMC. The causative pathogens of onychomycosis in southern Taiwan. Mycoses, 2005; 48:413–420.
11.
BramonoK, BudimuljaU. Epidemiology of onychomycosis in Indonesia: data obtained from three individual studies. Jpn J Med Mycol, 2005; 46:171–176.
12.
RomanoC, GianniC, DifonzoEM. Retrospective study of onychomycosis in Italy: 1985–2000. Mycoses, 2005; 48:42–44.
13.
EffendyI, LechaM, de ChauvinM, Di ChiacchioN, BaranR. European onychomycosis observatory. Epidemiology and clinical classification of onychomycosis. J Eur Acad Dermatol Venereol, 2005; 19:8–12.
14.
NadaH, MokhtarM, SaadS. Yeast infections as a cause of nail disease in the western province of Saudi Arabia. Egypt J Med Lab Sci, 2005; 14:1–7.
15.
IlkitM. Onychomycosis in Adana, Turkey: a 5-year study. Int J Dermatol, 2005; 44:851–854.
16.
IoannidouDJ, MarakiS, KrasagakisSK, ToscaA, TselentisY. The epidemiology of onychomycoses in Crete, Greece, between 1992 and 2001. J Eur Acad Dermatol Venereol, 2006; 20:170–174.
17.
SanjivA, ShaliniM, CharooH. Etiological agents of onychomycosis from a tertiary care hospital in Central Delhi, India. Indian J Fundam Appl Life Sci, 2011; 1:11–14.
18.
BrüggemannRJ, AlffenaarJW, BlijlevensNM. Clinical relevance of the pharmacokinetic interactions of azole antifungal drugs with other coadministered agents. Clin Infect Dis, 2009; 48:1441–1458.
19.
BaranR, KaoukhovA. Topical antifungal drugs for the treatment of onychomycosis: an overview of current strategies for monotherapy and combination therapy. J Eur Acad Dermatol Venereol, 2005; 19:21–29.
20.
ImhofM, LipovacM, KurzCH, BartaJ, VerhoevenHC, HuberJC. Propolis solution for the treatment of chronic vaginitis. Int J Gynecol Obstet, 2005; 89:127–132.
21.
OliveiraACP, LonghiniR, FrancoSL, SvidzinskiTIE. Antifungal activity of propolis extract against yeasts isolated from onychomycosis lesions. Memórias do Instituto Oswaldo Cruz, 2006; 101:493–497.
22.
YarfaniR, KhosraviAR, ShokriH. The antifungal activity of Iranian propolis samples against fluconazole-resistant Candida albicans strains isolated from HIV+ patients with oropharyngeal candidiasis. J ApiProduct ApiMedical Sci, 2010; 2:160–165.
23.
ShokriH, KhosraviAR, YalfaniR. Antifungal efficacy of propolis against fluconazole-resistant Candida glabrata isolates obtained from women with recurrent vulvovaginal candidiasis. Int J Gynecol Obstet, 2011; 114:158–159.
24.
KhosraviAR, YarahmadiS, BaiatM, ShokriH, PourkabirehM. Factors affecting the prevalence of yeasts in the oral cavity of patients with diabetes mellitus. J Mycol Méd, 2008; 18:83–88.
25.
NaeiniAR, NazeriM, ShokriH. Antifungal activity of Zataria multiflora, Pelargonium graveolens and Cuminum cyminum essential oils towards three species of Malassezia isolated from patients with pityriasis versicolor. J Mycol Méd, 2011; 21:87–91.
26.
Clinical Laboratory Standards Institute. Reference Method for Broth Dilution Antifungal Susceptibility Testing for Yeasts: Approved Standard, M27-A2. Wayne, PA: Clinical Laboratory Standards Institute, 2002.
27.
ConsolaroMEL, AlbertoniTAA, SvidzinskiAE, PeralataRM, SvidzinskiTIE. Vulvovaginal candidiasis is associated with the production of germ tubes by Candida albicans. Mycopathologia, 2005; 159:501–507.
28.
KamKM, AuWF, WongPY, CheungMM. Onychomycosis in Hong Kong. Int J Dermatol, 1997; 36:757–761.
29.
KirazM, YegenogluY, ErturanZ, AngO. The epidemiology of onychomycosis in Istanbul, Turkey. Mycoses, 1999; 42:323–329.
30.
PereaS, RamosMJ, GarauM, GonzalezA, NoriegaAR, del PalacioA. Prevalence and risk factors of Tinea unguium and Tinea pedis in the general population in Spain. J Clin Microbiol, 2000; 38:3226–3230.
31.
LopesJO, AlvesSH, MariCR, OliveiraLT, BrumLM, WestphalenJB, FurianFW, AltermannMJ. A ten year survey of onychomycosis in the central region of the Rio Grande do Sul, Brazil. Rev Inst Med Trop São Paulo, 1999; 41:147–149.
32.
ClaytonY. Clinical and mycological diagnostic aspects of onychomycoses and dermatomycoses. Clin Exp Dermatol, 1992; 17:37–40.
33.
EllabibMS, AgajM, KhalifaZ, KavanaghK. Yeasts of the genus Candida are the dominant cause of onychomycosis in Libyan women but not men: results of a 2-year surveillance study. Br J Dermatol, 2002; 146:1038–1041.
34.
BrilhanteRSN, CordeiroRA, MedranoDJA, RochaMFG, MonteiroAJ, CavalcanteCSP, MeirelesTEF, SidrimJJC. Onychomycosis in Ceará (Northeast Brazil): epidemiological and laboratory aspects. Mem Inst Oswaldo Cruz, 2002; 100:131–135.
35.
SilvaV, MorenoGA, ZarorL, de OliveiraE, FischmanO. Isolation of Malassezia spp. furfur from patient with onychomycosis. J Med Vet Mycol, 1997; 35:73–74.
36.
ChowdharyA, RandhawaHS, SharmaS, BrandtME, KumarS. Malassezia furfur in a case of onychomycosis: colonizer or etiologic agent?Med Mycol, 2005; 43:87–90.
37.
OtaC, UnterkircherC, FantinatoV, ShimizuMT. Antifungal activity of propolis on different species of Candida. Mycoses, 2001; 44:375–378.
38.
Dalben-DotaKF, ConsolaroMLC, SvidzinskiTIE, BruschiML. Antifungal activity of Brazilian propolis microparticles against yeasts isolated from vulvovaginal candidiasis. Evid Based Complement Alternat Med, 2011; 2011:1–8.
39.
Dalben-DotaKF, FariaMG, BruschiML, PellosoSM, Lopes-ConsolaroME, SvidzinskiTI. Antifungal activity of propolis extract against yeasts isolated from vaginal exudates. J Altern Complement Med, 2010; 16:285–290.
40.
KoçAN, SiliciS, KasapF, Hörmet-OzHT, Mavus-BulduH, ErcalBD. Antifungal activity of the honeybee products against Candida spp. and Trichosporon spp. J Med Food, 2011; 14:128–134.
41.
LilenbaumW, BarbosaAV. Avaliação da atividade antimicrobiana da própolis perante Malassezia pachydermatis in vitro. Rev Bras Med Vet, 1995; 16:248–251.
42.
CardosoRL, MaboniF, MachadoG, AlvesSH, de VargasAC. Antimicrobial activity of propolis extract against Staphylococcus coagulase positive and Malassezia pachydermatis of canine otitis. Vet Microbiol, 2010; 142:432–434.
43.
SiliciS, KocAN, MistikS. Comparison of in vitro activities of antifungal drugs and propolis against yeasts isolated from patients with superficial mycoses. Ann Microbiol, 2007; 57:269–272.
44.
HerreraCL, AlvearM, BarrientosL, MontenegroG, SalazarA. The antifungal effect of six commercial extracts of Chilean propolis on Candida spp. Cien Inv Agr, 2010; 37:75–84.
45.
KartalM, YildizS, KayaS, KurucuS, TopcuG. Antimicrobial activity of propolis samples from two different regions of Anatolia. J Ethnopharmacol, 2003; 86:69–73.
46.
SommezS, KirilmazL, YucesoyM, YucelB, YlmazB. The effect of bee propolis on oral pathogens and human gingival fibroblast. J Ethnopharmacol, 2005; 102:371–376.
